Inspire Medical Systems/$INSP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inspire Medical Systems
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Ticker
$INSP
Sector
Primary listing
NYSE
Employees
1,246
Headquarters
Website
INSP Metrics
BasicAdvanced
$2.3B
44.59
$1.74
1.15
-
Price and volume
Market cap
$2.3B
Beta
1.15
52-week high
$216.01
52-week low
$70.77
Average daily volume
1.1M
Financial strength
Current ratio
6.14
Quick ratio
4.698
Long term debt to equity
4.56
Total debt to equity
4.56
Interest coverage (TTM)
1,592.35%
Profitability
EBITDA (TTM)
52.187
Gross margin (TTM)
84.47%
Net profit margin (TTM)
6.17%
Operating margin (TTM)
4.81%
Effective tax rate (TTM)
9.64%
Revenue per employee (TTM)
$690,000
Management effectiveness
Return on assets (TTM)
3.38%
Return on equity (TTM)
8.07%
Valuation
Price to earnings (TTM)
44.586
Price to revenue (TTM)
2.681
Price to book
3.39
Price to tangible book (TTM)
3.39
Price to free cash flow (TTM)
27.167
Free cash flow yield (TTM)
3.68%
Free cash flow per share (TTM)
2.859
Growth
Revenue change (TTM)
22.05%
Earnings per share change (TTM)
756.73%
3-year revenue growth (CAGR)
41.99%
3-year earnings per share growth (CAGR)
2.88%
What the Analysts think about INSP
Analyst ratings (Buy, Hold, Sell) for Inspire Medical Systems stock.
Bulls say / Bears say
Q2 2025 revenue reached $217.1 million, up 11% compared to last year, supported by U.S. growth of 10% and international growth of 23%, signaling strong market uptake for its OSA therapy.
Sustained a strong gross margin of 84.0% in Q2 2025, enabling continued investment in new products and global expansion.
Finished Q2 2025 with $300.9 million in cash and short-term investments, ensuring ample liquidity for R&D and long-term growth.
Reduced its full-year 2025 revenue outlook to $900–910 million and EPS outlook to $0.40–0.50, down from prior guidance of $940–955 million and $2.20–2.30, indicating operational challenges and weaker demand.
Moved from an operating profit of $5.1 million in the prior year to an operating loss of $3.3 million in Q2 2025, reflecting increased operational and transition expenses tied to the Inspire V launch.
Shares dropped 32.4% following Q2 results after management noted that competition from GLP-1 drugs such as Zepbound and Wegovy was a major drag on procedure volumes, leading Leerink Partners to lower its price target to $116.
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
INSP Financial Performance
Revenues and expenses
INSP Earnings Performance
Company profitability
INSP News
AllArticlesVideos
BAK Investors Have Opportunity to Join Braskem S.A. Fraud Investigation with the Schall Law Firm
Business Wire3 days ago
ALGN Investors Have Opportunity to Join Align Technology, Inc. Fraud Investigation with the Schall Law Firm
Business Wire2 months ago
Inspire Medical Stock Strays Off Course Amid Structural Setback
Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inspire Medical Systems stock?
Inspire Medical Systems (INSP) has a market cap of $2.3B as of October 14, 2025.
What is the P/E ratio for Inspire Medical Systems stock?
The price to earnings (P/E) ratio for Inspire Medical Systems (INSP) stock is 44.59 as of October 14, 2025.
Does Inspire Medical Systems stock pay dividends?
No, Inspire Medical Systems (INSP) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Inspire Medical Systems dividend payment date?
Inspire Medical Systems (INSP) stock does not pay dividends to its shareholders.
What is the beta indicator for Inspire Medical Systems?
Inspire Medical Systems (INSP) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.